Humacyte's bioengineered vessel shows low atherosclerosis susceptibility in long-term clinical study
HUMA•Humacyte said an analysis of 52 patients across five clinical trials found low atherosclerosis susceptibility in its bioengineered vessel, including in vessels implanted for more than five years.
1. Long-term clinical findings
Humacyte announced findings of low atherosclerosis susceptibility, minimal lipid buildup and no vulnerable plaques in its acellular tissue-engineered vessel. The analysis covered 52 patients across five clinical trials, including vessels implanted for more than five years, and was presented at the 2026 ISVTE-ISACB Joint Meeting in Miami.




